Royalty Pharma reported $690.1 million in revenue for Q3 2026.

Item 1. Condensed Consolidated Financial Statements 1

Notes to Condensed Consolidated Financial Statements (unaudited) 6

Item 6. Exhibits 90

Signatures 90

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains statements reflecting our views about our future performance that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "target," "forecast," "guidance," "goal," "predicts," "project," "potential" or "continue," the negative of these terms and other comparable terminology. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about us, our current and prospective assets, our industry, our beliefs and our assumptions. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of the numerous risks outlined in Part II under Item 1A. under "Risk Factors."

These risks and uncertainties include factors related to, among other topics:

• sales risks of biopharmaceutical products on which we receive royalties;

• uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add development-stage product candidates to our product portfolio;

• the assumptions underlying our busine

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ROYALTY PHARMA PLC CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)

(Unaudited)

As of September 30, As of December 31,

2026 2025

Assets

Current assets

Available for sale debt securities 31,200 18,800

Available for sale debt securities 350,000 419,000

Liabilities and shareholders' equity

Current liabilities

Distributions payable to non-controlling interests $ 71,059 $ 72,825

Accounts payable and accrued liabilities 31,422 19,404

Interest payable 19,688 110,818

Current portion of long-term debt 996,973 380,000

Commitments and contingencies

Shareholders' equity

— —

— —

Total liabilities and shareholders' equity $ 19,461,223 $ 19,620,780

Se